Literature DB >> 26149564

Response.

Jason Rho1, Nancy Ho2, Vinay Prasad3.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26149564      PMCID: PMC5831562          DOI: 10.1378/chest.15-0837

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  5 in total

1.  Side-effects of roflumilast.

Authors:  Steve Gupta
Journal:  Lancet       Date:  2012-02-25       Impact factor: 79.321

2.  Counterpoint: were industry-sponsored roflumilast trials appropriate? No.

Authors:  Jason Rho; Nancy Ho; Vinay Prasad
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

3.  Point: were industry-sponsored roflumilast trials appropriate? Yes.

Authors:  Samy Suissa; Klaus F Rabe
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

4.  Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

Authors:  Fernando J Martinez; Peter M A Calverley; Udo-Michael Goehring; Manja Brose; Leonardo M Fabbri; Klaus F Rabe
Journal:  Lancet       Date:  2015-02-13       Impact factor: 79.321

5.  Roflumilast added to triple therapy in patients with severe COPD: a real life study.

Authors:  Mariana Muñoz-Esquerre; Marta Diez-Ferrer; Concepción Montón; Xavier Pomares; Marta López-Sánchez; Daniel Huertas; Frederic Manresa; Jordi Dorca; Salud Santos
Journal:  Pulm Pharmacol Ther       Date:  2014-10-30       Impact factor: 3.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.